Skip to content Skip to footer
Subscribe Now
Merck Animal Health
NEWS

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

Shots: The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025 Mometamax Single has shown favorable efficacy, with 80.5% resolution of clinical signs in dogs vs 19.6% with PBO Mometamax Single is a single-dose in-clinic treatment for otitis…
May 5, 2025

Read more

Repare Therapeutics & DCx Biotherapeutics
NEWS

Repare Therapeutics Out-Licenses its Discovery Platforms to DCx Biotherapeutics

Shots: Repare has out-licensed its discovery platform incl. SNIPRx, SNIPRx-surf, & STEP2 , along with certain intellectual property to DCx As per the deal, Repare will get $4M as upfront & near-term payments, 9.99% equity in DCx with dilution protection, & future potential out-licensing, clinical & commercial milestones, with low-single digit tiered sales royalties; Repare will…
May 2, 2025

Read more

Astrazeneca
NEWS

AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings of Breztri Aerosphere for Uncontrolled Asthma

Shots: AstraZeneca has reported P-III (LOGOS & KALOS) trial results evaluating Breztri Aerosphere (BGF; 320/28.8/9.6μg or 320/14.4/9.6μg) vs PT009 (ICS/LABA via Aerosphere) & Symbicort pressurized metered-dose inhaler (pMDI) in pts (n=~4400) with uncontrolled asthma Trial met its 1EP, with BGF 320/28.8/9.6μg showing significant improvement in forced expiratory volume in 1 second (FEV1) AUC 0 to 3hrs. at…
May 2, 2025

Read more

Merck Animal Health & AmacaThera
NEWS

Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use

Shots: Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary use Collaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug delivery AmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force…
May 2, 2025

Read more

Brightseed and Haleon
NEWS

Brightseed and Haleon Collaborate to Discover Small Molecule for Human Health Innovation by Leveraging AI Platform Forager

Shots: Haleon and Brightseed have partnered to accelerate the discovery of plant-based bioactive compounds using Brightseed’s AI platform, Forager, supporting Haleon to create innovative health solutions Forager will be directly accessible to Haleon scientists, enabling AI-powered identification of natural compounds and their health-related mechanisms, streamlining R&D and product development Forager bioactive discovery has already demonstrated…
May 2, 2025

Read more

OcuSciences
NEWS

OcuSciences’ OcuMet Beacon Receives the US FDA Clearance for Retinal Health Assessment

Shots: OcuSciences has received the US FDA clearance for OcuMet Beacon, a non-invasive confocal scanning ophthalmoscope designed for infrared & autofluorescence imaging of the human retina, with or without the use of a mydriatic agent Peer-reviewed clinical studies have showed favorable safety & clinical utility of the OcuMet Beacon, with dozen new studies presented at…
May 2, 2025

Read more

Amylyx
NEWS

Amylyx Pharmaceuticals Reports the First Participant Dosing in P-III (LUCIDITY) Study Evaluating Avexitide in PBH

S Shots: Amylyx has dosed the first participant in its pivotal P-III (LUCIDITY) study of avexitide (90mg) for post-bariatric hypoglycemia (PBH), with recruitment completion expected in 2025 and topline data in the H1’26 The P-III (LUCIDITY) study evaluating avexitide (QD) vs PBO in ~75 PBH patients post Roux-en-Y gastric bypass surgery includes a 6wks. screening…
May 1, 2025

Read more

Load more